Back to Stocks

DRIO

DarioHealth Corp.
2 filings tracked
healthcaredigital therapeuticsMICRO (<$300M)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

DarioHealth is currently executing a disciplined operational pivot, transitioning from a high-burn growth phase to a leaner, consumer-centric health intelligence platform.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the narrative of a turnaround, the latest filing reveals a company in a precarious financial position, characterized by a formal 'going concern' warning.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every DRIO filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 report presents a stark contrast between operational efficiency and financial stability. On one hand, DarioHealth has successfully reduced its burn rate and grown its consumer segment, suggesting that the core product has value and the cost structure is becoming more sustainable. The reduction in R&D and marketing spend indicates a shift toward a more disciplined approach to growth. However, these gains are overshadowed by a looming liquidity crisis and a heavy debt load. The 'substantial doubt' regarding the company's ability to continue as a going concern is a critical signal that the market cannot ignore. Investors are left weighing the potential of a clinically validated digital health platform against the immediate risk of insolvency or massive dilution via the ATM program. The path forward depends entirely on whether the consumer growth can accelerate fast enough to offset the interest burden and operational losses before the current cash reserves vanish.

Selected Quarter

Core Takeaway

DarioHealth is successfully reducing its burn rate and pivoting toward consumer growth, but its cash runway is dangerously short, triggering a going concern alert.

Investor Lens

The trade-off is between a clinically validated platform with improving unit economics and a balance sheet that may not survive the year.

Watch Next

Utilization of the $20M ATM facility and the ability to maintain the $10,000 minimum liquid assets covenant.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.05Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 13

Operating expenses reduced by over 21% year-over-year.

margin expansion
40%
bearishMay 13

Company reported a net loss of $8.25 million and issued a going concern warning.

earnings miss
70%
neutralMay 13

Established a $20 million ATM facility to fund ongoing operations.

capital raise
60%
bullishMay 13

Debt principal repayments deferred until May 2028.

debt restructure
50%
bullishMay 13

Operating expenses reduced by over 21% year-over-year.

margin expansion
40%
bearishMay 13

Company reported a net loss of $8.25 million and issued a going concern warning.

earnings miss
70%
neutralMay 13

Established a $20 million ATM facility to fund ongoing operations.

capital raise
60%
bullishMay 13

Debt principal repayments deferred until May 2028.

debt restructure
50%

Filing History

10-QMay 13, 2026
Expand Sequence

The Q1 2026 report presents a stark contrast between operational efficiency and financial stability. On one hand, DarioHealth has successfully reduced its burn rate and grown its consumer segment, suggesting that the core product has value and the cost structure is becoming more sustainable. The reduction in R&D and marketing spend indicates a shift toward a more disciplined approach to growth. However, these gains are overshadowed by a looming liquidity crisis and a heavy debt load. The 'substantial doubt' regarding the company's ability to continue as a going concern is a critical signal that the market cannot ignore. Investors are left weighing the potential of a clinically validated digital health platform against the immediate risk of insolvency or massive dilution via the ATM program. The path forward depends entirely on whether the consumer growth can accelerate fast enough to offset the interest burden and operational losses before the current cash reserves vanish.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.